{"id":32005,"date":"2025-05-02T09:01:36","date_gmt":"2025-05-02T09:01:36","guid":{"rendered":"https:\/\/ghostai.pro\/blog\/fda-approves-first-new-antibiotic-for-utis-in-nearly-30-years\/"},"modified":"2025-05-02T09:01:36","modified_gmt":"2025-05-02T09:01:36","slug":"fda-approves-first-new-antibiotic-for-utis-in-nearly-30-years","status":"publish","type":"post","link":"https:\/\/ghostai.pro\/blog\/fda-approves-first-new-antibiotic-for-utis-in-nearly-30-years\/","title":{"rendered":"FDA approves first new antibiotic for UTIs in nearly 30 years"},"content":{"rendered":"<p>The FDA&#8217;s approval of Blujepa, the first new antibiotic for urinary tract infections (UTIs) in nearly 30 years, is a significant development in the fight against drug-resistant bacteria. This class of antibiotics, known as triazaacenaphthylenes, targets two key enzymes that E. coli bacteria need to replicate and survive. The approval comes at a crucial time when more than 2.8 million antimicrobial-resistant infections occur annually in the U.S., according to the Centers for Disease Control and Prevention (CDC). A 2019 study found resistance to at least one drug in over 92% of bacteria that can cause UTIs, with around 80% showing resistance to at least two drugs. The development of new antibiotics like Blujepa is crucial for reducing the risk of drug-resistant infections and maintaining effective treatment options. Dr. Candace Granberg, a pediatric urologist and surgeon-in-chief at Mayo Clinic Children&#8217;s in Rochester, Minnesota, emphasizes that &#8220;we absolutely need new antibiotics for uncomplicated UTIs.&#8221; The approval of Blujepa highlights the importance of continued research and development to combat drug resistance and ensure effective treatment options remain available.<\/p>\n<p>[Original Article](https:\/\/www.nbcnews.com\/health\/health-news\/fda-approves-first-new-antibiotic-utis-nearly-30-years-rcna197953) #approves #first [Visit GhostAI](https:\/\/ghostai.pro\/)<\/p>\n<p>[Join our Discord](https:\/\/discord.com\/invite\/zgKZUJ6V8z)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA&#8217;s approval of Blujepa, the first new antibiotic for urinary tract infections (UTIs) in nearly 30 years, is a significant development in the fight against drug-resistant bacteria. This class of antibiotics, known as triazaacenaphthylenes, targets two key enzymes that E. coli bacteria need to replicate and survive. The approval comes at a crucial time [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-container-style":"default","site-container-layout":"default","site-sidebar-layout":"default","disable-article-header":"default","disable-site-header":"default","disable-site-footer":"default","disable-content-area-spacing":"default","footnotes":""},"categories":[18],"tags":[],"class_list":["post-32005","post","type-post","status-publish","format-standard","hentry","category-ghostai"],"_links":{"self":[{"href":"https:\/\/ghostai.pro\/blog\/wp-json\/wp\/v2\/posts\/32005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ghostai.pro\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ghostai.pro\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ghostai.pro\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ghostai.pro\/blog\/wp-json\/wp\/v2\/comments?post=32005"}],"version-history":[{"count":0,"href":"https:\/\/ghostai.pro\/blog\/wp-json\/wp\/v2\/posts\/32005\/revisions"}],"wp:attachment":[{"href":"https:\/\/ghostai.pro\/blog\/wp-json\/wp\/v2\/media?parent=32005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ghostai.pro\/blog\/wp-json\/wp\/v2\/categories?post=32005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ghostai.pro\/blog\/wp-json\/wp\/v2\/tags?post=32005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}